eMed pocketed $200 million in funding to build out its AI agentic platform and offer new models for employers, including programs for GLP-1 medications.
The funding round boosts the company's valuation to $2 billion. AON Consulting led the round along with prominent investors former NFL player Tom Brady, founding chief wellness officer, Jeff Aronin, founder, chairman and CEO of Paragon Biosciences; Ara Cohen, co-founder and co-managing Member of Knighthead Capital Management; Antonio Gracias, founder and CEO of Valor Equity Partners; Joe Lonsdale, founder and managing partner at 8VC and co-founder of Palantir; R.J. Melman, CEO, Lettuce Entertain You Restaurants; Tom Ricketts, chairman of the Chicago Cubs; and former X CEO and current eMed CEO Linda Yaccarino.
The company plans to use the fresh capital to support and fund a new capitated model designed to help employers bend the healthcare cost curve. GLP-1 medications are the most requested workplace benefit, yet only one in five companies provide the benefit, according to the company.
"I believe eMed's empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I've chosen to invest both my time as Founding Chief Wellness Officer and my capital in the company," Brady said in a statement.
The company provides clinically managed GLP-1 programs for employers. eMed boasts 90% member adherence, more than double the industry norm, with an average weight loss of 21 pounds. In addition, 99% of program participants see improvement in at least one key biomarker within six months.